These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15867254)

  • 1. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.
    Beaudry P; Force J; Naumov GN; Wang A; Baker CH; Ryan A; Soker S; Johnson BE; Folkman J; Heymach JV
    Clin Cancer Res; 2005 May; 11(9):3514-22. PubMed ID: 15867254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.
    Langenkamp E; Zwiers PJ; Moorlag HE; Leenders WP; St Croix B; Molema G
    Anticancer Drugs; 2012 Feb; 23(2):161-72. PubMed ID: 22075979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
    Yano S; Muguruma H; Matsumori Y; Goto H; Nakataki E; Edakuni N; Tomimoto H; Kakiuchi S; Yamamoto A; Uehara H; Ryan A; Sone S
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8789-98. PubMed ID: 16361567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
    McCarty MF; Wey J; Stoeltzing O; Liu W; Fan F; Bucana C; Mansfield PF; Ryan AJ; Ellis LM
    Mol Cancer Ther; 2004 Sep; 3(9):1041-8. PubMed ID: 15367698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
    Ciardiello F; Caputo R; Damiano V; Caputo R; Troiani T; Vitagliano D; Carlomagno F; Veneziani BM; Fontanini G; Bianco AR; Tortora G
    Clin Cancer Res; 2003 Apr; 9(4):1546-56. PubMed ID: 12684431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy.
    Mehran R; Nilsson M; Khajavi M; Du Z; Cascone T; Wu HK; Cortes A; Xu L; Zurita A; Schier R; Riedel B; El-Zein R; Heymach JV
    Cancer Res; 2014 May; 74(10):2731-41. PubMed ID: 24626092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.
    Wu W; Onn A; Isobe T; Itasaka S; Langley RR; Shitani T; Shibuya K; Komaki R; Ryan AJ; Fidler IJ; Herbst RS; O'Reilly MS
    Mol Cancer Ther; 2007 Feb; 6(2):471-83. PubMed ID: 17308046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
    Wedge SR; Ogilvie DJ; Dukes M; Kendrew J; Chester R; Jackson JA; Boffey SJ; Valentine PJ; Curwen JO; Musgrove HL; Graham GA; Hughes GD; Thomas AP; Stokes ES; Curry B; Richmond GH; Wadsworth PF; Bigley AL; Hennequin LF
    Cancer Res; 2002 Aug; 62(16):4645-55. PubMed ID: 12183421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis.
    Shaked Y; Bertolini F; Man S; Rogers MS; Cervi D; Foutz T; Rawn K; Voskas D; Dumont DJ; Ben-David Y; Lawler J; Henkin J; Huber J; Hicklin DJ; D'Amato RJ; Kerbel RS
    Cancer Cell; 2005 Jan; 7(1):101-11. PubMed ID: 15652753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating endothelial cells as a novel marker of angiogenesis.
    Mancuso P; Calleri A; Cassi C; Gobbi A; Capillo M; Pruneri G; Martinelli G; Bertolini F
    Adv Exp Med Biol; 2003; 522():83-97. PubMed ID: 12674213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.
    Williams KJ; Telfer BA; Brave S; Kendrew J; Whittaker L; Stratford IJ; Wedge SR
    Clin Cancer Res; 2004 Dec; 10(24):8587-93. PubMed ID: 15623642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.
    Damiano V; Melisi D; Bianco C; Raben D; Caputo R; Fontanini G; Bianco R; Ryan A; Bianco AR; De Placido S; Ciardiello F; Tortora G
    Clin Cancer Res; 2005 Aug; 11(15):5639-44. PubMed ID: 16061883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.
    Tuccillo C; Romano M; Troiani T; Martinelli E; Morgillo F; De Vita F; Bianco R; Fontanini G; Bianco RA; Tortora G; Ciardiello F
    Clin Cancer Res; 2005 Feb; 11(3):1268-76. PubMed ID: 15709198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.
    Matsumori Y; Yano S; Goto H; Nakataki E; Wedge SR; Ryan AJ; Sone S
    Oncol Res; 2006; 16(1):15-26. PubMed ID: 16783964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
    Conrad C; Ischenko I; Köhl G; Wiegand U; Guba M; Yezhelyev M; Ryan AJ; Barge A; Geissler EK; Wedge SR; Jauch KW; Bruns CJ
    Anticancer Drugs; 2007 Jun; 18(5):569-79. PubMed ID: 17414626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.
    Rich JN; Sathornsumetee S; Keir ST; Kieran MW; Laforme A; Kaipainen A; McLendon RE; Graner MW; Rasheed BK; Wang L; Reardon DA; Ryan AJ; Wheeler C; Dimery I; Bigner DD; Friedman HS
    Clin Cancer Res; 2005 Nov; 11(22):8145-57. PubMed ID: 16299247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phloroglucinol inhibits the bioactivities of endothelial progenitor cells and suppresses tumor angiogenesis in LLC-tumor-bearing mice.
    Kwon YH; Jung SY; Kim JW; Lee SH; Lee JH; Lee BY; Kwon SM
    PLoS One; 2012; 7(4):e33618. PubMed ID: 22496756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer.
    Shibuya K; Komaki R; Shintani T; Itasaka S; Ryan A; Jürgensmeier JM; Milas L; Ang K; Herbst RS; O'Reilly MS
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1534-43. PubMed ID: 17889445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.